MX2019000933A - Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr). - Google Patents
Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr).Info
- Publication number
- MX2019000933A MX2019000933A MX2019000933A MX2019000933A MX2019000933A MX 2019000933 A MX2019000933 A MX 2019000933A MX 2019000933 A MX2019000933 A MX 2019000933A MX 2019000933 A MX2019000933 A MX 2019000933A MX 2019000933 A MX2019000933 A MX 2019000933A
- Authority
- MX
- Mexico
- Prior art keywords
- rsv
- mva
- respiratory syncytial
- virus
- modified vaccinia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/065—Poxviridae, e.g. avipoxvirus
- C07K14/07—Vaccinia virus; Variola virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18571—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a cepas de virus vaccinia Ankara modificado (MVA) recombinan te como vacunas mejoradas contra la infección por el virus sincicial respiratorio (virus VSR) y a productos, métodos y usos relacionados. Específicamente, se proporcionan en la presente vectores de MVA recombinan te modificados genéticamente que comprenden al menos una secuencia de nucleótidos que codifica un determinante antigénico de una glicoproteína de membrana de VSR y al menos una secuencia de nucleótidos que codifica un determinante antigénico de una proteína de la nucleocápside de VSR. También se proporcionan en la presente productos, métodos y usos de éste, por ejemplo, apropiados para provocar una respuesta inmunológica en un sujeto o apropiados para diagnosticar una infección de VSR, así como también para determinar si un sujeto está en riesgo de una infección por VSR recurrente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261678367P | 2012-08-01 | 2012-08-01 | |
EP12005594 | 2012-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019000933A true MX2019000933A (es) | 2022-06-27 |
Family
ID=46614287
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015001479A MX362511B (es) | 2012-08-01 | 2013-03-15 | Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr). |
MX2023003746A MX2023003746A (es) | 2012-08-01 | 2015-01-30 | Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr). |
MX2019000933A MX2019000933A (es) | 2012-08-01 | 2015-01-30 | Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr). |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015001479A MX362511B (es) | 2012-08-01 | 2013-03-15 | Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr). |
MX2023003746A MX2023003746A (es) | 2012-08-01 | 2015-01-30 | Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr). |
Country Status (19)
Country | Link |
---|---|
US (6) | US9480738B2 (es) |
EP (2) | EP3656396A1 (es) |
JP (2) | JP6523955B2 (es) |
KR (3) | KR20220119527A (es) |
CN (2) | CN109266622B (es) |
AU (1) | AU2013298915B2 (es) |
BR (1) | BR112015002131B1 (es) |
CA (2) | CA3158572A1 (es) |
CY (1) | CY1122717T1 (es) |
EA (2) | EA031453B1 (es) |
HK (1) | HK1205459A1 (es) |
IL (1) | IL236744B (es) |
IN (1) | IN2015DN01448A (es) |
MX (3) | MX362511B (es) |
MY (1) | MY171498A (es) |
NZ (1) | NZ704005A (es) |
SG (1) | SG11201500696VA (es) |
SI (1) | SI2879702T1 (es) |
WO (1) | WO2014019718A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2879702T3 (da) * | 2012-08-01 | 2020-02-24 | Bavarian Nordic As | Rekombinant modificeret vacciniavirus ankara (mva)-vaccine mod respiratorisk syncytialvirus (rsv) |
JP6480875B2 (ja) * | 2013-03-15 | 2019-03-13 | バヴァリアン・ノルディック・アクティーゼルスカブ | 単一高用量のmvaは、新生児及び幼児において防御免疫応答を引き起こす |
JP6664338B2 (ja) | 2014-06-13 | 2020-03-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組合せ物 |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
CA2988654A1 (en) | 2015-06-12 | 2016-12-15 | Glaxosmithkline Biologicals S.A. | Adenovirus polynucleotides and polypeptides |
FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
BR112019020661A2 (pt) | 2017-04-04 | 2020-05-05 | University Of Washington | nanoestruturas de proteína de auto-montagem que exibem proteínas f de paramixovírus e/ou pneumovírus e seu uso |
EP3624851A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
WO2018211419A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
KR20200101394A (ko) | 2017-12-20 | 2020-08-27 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 엡스타인-바 바이러스 항원 구축물 |
AU2019228551A1 (en) | 2018-02-28 | 2020-10-15 | University Of Washington | Self-assembling nanostructure vaccines |
US20210187100A1 (en) * | 2018-09-06 | 2021-06-24 | Bavarian Nordic A/S | Storage Improved Poxvirus Compositions |
US20220195016A1 (en) * | 2019-04-18 | 2022-06-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Biological and synthetic molecules inhibiting respiratory syncytial virus infection |
CA3148026A1 (en) * | 2019-08-13 | 2021-02-18 | Vyjayanthi Krishnan | Therapeutic agent effectiveness and its route of administration |
KR20220153587A (ko) | 2020-03-12 | 2022-11-18 | 버베리안 노딕 에이/에스 | 폭스바이러스 안정성을 개선하는 조성물 |
AU2022338199A1 (en) | 2021-09-03 | 2024-03-14 | Bavarian Nordic A/S | Utilization of micro-rna for downregulation of cytotoxic transgene expression by modified vaccinia virus ankara (mva) |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
US5639853A (en) | 1987-09-29 | 1997-06-17 | Praxis Biologics, Inc. | Respiratory syncytial virus vaccines |
US5223254A (en) | 1987-09-29 | 1993-06-29 | Praxis Biologics, Inc. | Respiratory syncytial virus: vaccines |
JP2716503B2 (ja) | 1987-12-23 | 1998-02-18 | ジ・アップジョン・カンパニー | ヒト呼吸系シンシチウムウイルスの糖蛋白類の免疫原性セグメントを含有するキメラ糖蛋白類 |
CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
JPH05509231A (ja) | 1990-07-24 | 1993-12-22 | ザ ユーエイビー リサーチ ファンデーション | ウシrsウイルスの組換えdna、タンパク質ワクチン、抗体、および形質転換細胞の使用法 |
US6730305B1 (en) | 2000-05-08 | 2004-05-04 | The Uab Research Foundation | Nucleotide sequences encoding bovine respiratory syncytial virus immunogenic proteins |
GB9200117D0 (en) | 1992-01-06 | 1992-02-26 | Connaught Lab | Production of recombinant chimeric proteins for vaccine use |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
DE69509103T2 (de) | 1994-08-25 | 1999-09-30 | Pepscan Systems Bv | Antigene peptide abgeleitet vom g-protein des rsv (respiratorisches synzytialvirus) für die typen- und subtypen spezifische diagnose einer rsv-infektionen |
FR2726471B1 (fr) | 1994-11-07 | 1997-01-31 | Pf Medicament | Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins |
US6083925A (en) | 1995-06-07 | 2000-07-04 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
US6019980A (en) | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
US6180398B1 (en) | 1996-07-12 | 2001-01-30 | Virogeneitics Corporation | Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation |
US6020182A (en) | 1996-07-12 | 2000-02-01 | Connaught Laboratories Limited | Subunit respiratory syncytial virus vaccine preparation |
FR2751229B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
US6699478B1 (en) | 1997-09-19 | 2004-03-02 | Wyeth Holdings Corporation | Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus |
FR2798857B1 (fr) * | 1999-09-23 | 2003-06-06 | Pf Medicament | Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale |
US6651655B1 (en) | 2000-01-18 | 2003-11-25 | Quadrant Technologies Limited | Inhaled vaccines |
GB0024089D0 (en) * | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
SG106639A1 (en) | 2000-10-10 | 2004-10-29 | Gen Electric | Apparatus and method for introducing small amounts of refractory elements into a vapor deposition coating |
EP1334119B2 (en) | 2000-10-18 | 2018-11-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Compositions and methods for modulating rsv infection and immunity |
EE05680B1 (et) | 2000-11-23 | 2013-10-15 | Bavarian Nordic A/S | Muundatud vaktsiiniaviirus, selle valmistamine ja kasutamine, seda sisaldav farmatseutiline kompositsioon ning vaktsiin |
US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
FR2827605B1 (fr) | 2001-07-20 | 2004-07-16 | Pf Medicament | Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin |
EP1456230A2 (en) | 2001-12-04 | 2004-09-15 | Bavarian Nordic A/S | Flavivirus ns1 subunit vaccine |
JP4895505B2 (ja) | 2002-05-16 | 2012-03-14 | バヴァリアン・ノルディック・アクティーゼルスカブ | 変異ワクシニアウイルスアンカラ(mva)ゲノム中の挿入部位としての遺伝子間領域 |
US7368537B2 (en) | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
WO2006023029A2 (en) | 2004-06-16 | 2006-03-02 | The Johns Hopkins University | The cysteine-rich region of respiratory syncytial virus and methods of use therefor |
EP1793852A1 (en) * | 2004-08-27 | 2007-06-13 | Panacea Biotec Ltd. | Inactivated poliomyelitis vaccine derived from sabin strain of polio virus |
EP2062246A4 (en) * | 2006-08-18 | 2010-09-29 | Univ North Carolina | CHIMERIC VIRAL VACCINES |
EP2099486A2 (en) * | 2006-11-30 | 2009-09-16 | Government Of The United States Of America, As Represented by the Secretary | Codon modified immunogenic compositions and methods of use |
DE102006060799A1 (de) | 2006-12-21 | 2008-06-26 | RUHR-UNIVERSITäT BOCHUM | RSV F-Protein und seine Verwendung |
JP2010522540A (ja) * | 2007-03-21 | 2010-07-08 | アイディー バイオメディカル コーポレイション オブ ケベック | キメラ抗原 |
KR100938105B1 (ko) * | 2007-09-21 | 2010-01-21 | 이화여자대학교 산학협력단 | 호흡기 신시치아 바이러스 백신 |
AU2008340949A1 (en) | 2007-12-24 | 2009-07-02 | Glaxosmithkline Biologicals S.A. | Recombinant RSV antigens |
WO2010039224A2 (en) | 2008-09-30 | 2010-04-08 | University Of Massachusetts Medical School | Respiratory syncytial virus (rsv) sequences for protein expression and vaccines |
WO2010059689A2 (en) | 2008-11-18 | 2010-05-27 | Ligocyte Pharmaceuticals, Inc. | Rsv f vlps and methods of manufacture and use thereof |
CA2742247C (en) | 2008-11-21 | 2017-07-04 | Bavarian Nordic A/S | Vector comprising multiple homologous nucleotide sequences |
EP3718566B1 (en) * | 2008-12-09 | 2024-06-12 | Novavax, Inc. | Modified rsv f proteins and methods of their use |
US20110318376A1 (en) | 2008-12-24 | 2011-12-29 | University Of Rochester | Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins |
US9492531B2 (en) | 2009-06-24 | 2016-11-15 | Glaxosmithkline Biologicals Sa | Recombinant RSV vaccines |
MX2012000036A (es) | 2009-06-24 | 2012-02-28 | Glaxosmithkline Biolog Sa | Vacuna. |
DK3178490T3 (da) * | 2009-07-15 | 2022-06-20 | Glaxosmithkline Biologicals Sa | RSV F-proteinsammensætninger og fremgangsmåder til fremstilling af disse |
CA2770304C (en) * | 2009-08-04 | 2019-11-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention | Anti-rsv immunogens and methods of immunization |
CN102695523A (zh) | 2009-09-10 | 2012-09-26 | 诺华有限公司 | 针对呼吸道疾病的组合疫苗 |
WO2011046925A1 (en) | 2009-10-12 | 2011-04-21 | Technovax, Inc. | Respiratory syncytial virus (rsv) virus-like particles (vlps) |
US20120318376A1 (en) | 2009-11-12 | 2012-12-20 | Trojan Technologies | Cleaning apparatus, radiation source module and fluid treatment system |
NZ600629A (en) | 2010-01-28 | 2014-12-24 | Bavarian Nordic As | Vaccinia virus mutants containing the major genomic deletions of mva |
CN103037898B (zh) | 2010-07-07 | 2016-06-29 | 人工细胞科技公司 | 呼吸道合胞病毒抗原组合物和方法 |
WO2012080477A1 (en) * | 2010-12-17 | 2012-06-21 | Philip Morris Products S.A. | Container having interactive surface elements including design element |
WO2012085936A2 (en) * | 2010-12-20 | 2012-06-28 | Panacea Biotech Ltd | Recombinant respiratory syncytial virus plasmids and vaccines |
WO2012089231A1 (en) | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
-
2013
- 2013-03-15 EP EP19211547.5A patent/EP3656396A1/en not_active Withdrawn
- 2013-03-15 SG SG11201500696VA patent/SG11201500696VA/en unknown
- 2013-03-15 SI SI201331652T patent/SI2879702T1/sl unknown
- 2013-03-15 EA EA201590304A patent/EA031453B1/ru not_active IP Right Cessation
- 2013-03-15 CA CA3158572A patent/CA3158572A1/en active Pending
- 2013-03-15 MX MX2015001479A patent/MX362511B/es active IP Right Grant
- 2013-03-15 KR KR1020227028479A patent/KR20220119527A/ko not_active Application Discontinuation
- 2013-03-15 AU AU2013298915A patent/AU2013298915B2/en active Active
- 2013-03-15 CA CA2879915A patent/CA2879915C/en active Active
- 2013-03-15 EP EP13717721.8A patent/EP2879702B9/en active Active
- 2013-03-15 WO PCT/EP2013/055483 patent/WO2014019718A1/en active Application Filing
- 2013-03-15 CN CN201811121036.XA patent/CN109266622B/zh active Active
- 2013-03-15 JP JP2015524681A patent/JP6523955B2/ja active Active
- 2013-03-15 IN IN1448DEN2015 patent/IN2015DN01448A/en unknown
- 2013-03-15 KR KR1020217017594A patent/KR102435054B1/ko active IP Right Grant
- 2013-03-15 EA EA201891945A patent/EA201891945A3/ru unknown
- 2013-03-15 CN CN201380040909.3A patent/CN104540520B/zh active Active
- 2013-03-15 NZ NZ704005A patent/NZ704005A/en unknown
- 2013-03-15 MY MYPI2015700265A patent/MY171498A/en unknown
- 2013-03-15 BR BR112015002131-0A patent/BR112015002131B1/pt active IP Right Grant
- 2013-03-15 US US14/417,779 patent/US9480738B2/en active Active
- 2013-03-15 KR KR1020157005085A patent/KR102264852B1/ko active IP Right Grant
-
2015
- 2015-01-15 IL IL236744A patent/IL236744B/en unknown
- 2015-01-30 MX MX2023003746A patent/MX2023003746A/es unknown
- 2015-01-30 MX MX2019000933A patent/MX2019000933A/es unknown
- 2015-06-25 HK HK15106038.4A patent/HK1205459A1/xx unknown
-
2016
- 2016-10-14 US US15/294,480 patent/US9717787B2/en active Active
-
2017
- 2017-07-28 US US15/662,382 patent/US10124058B2/en active Active
-
2018
- 2018-11-09 US US16/185,125 patent/US10532094B2/en active Active
-
2020
- 2020-01-09 US US16/737,969 patent/US10946089B2/en active Active
- 2020-01-21 CY CY20201100050T patent/CY1122717T1/el unknown
-
2021
- 2021-03-15 US US17/202,230 patent/US20210196814A1/en not_active Abandoned
-
2023
- 2023-07-18 JP JP2023116634A patent/JP2023139095A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019000933A (es) | Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr). | |
WO2016109792A3 (en) | Novel multivalent nanoparticle-based vaccines | |
WO2016034678A3 (en) | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine | |
NZ630753A (en) | Vaccine against rsv | |
MX350274B (es) | Vacunas para hsv-2. | |
ZA201707985B (en) | Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine | |
MX2014009845A (es) | Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos. | |
MY180109A (en) | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza | |
MX2019003682A (es) | Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas. | |
MX345150B (es) | Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1. | |
WO2012106231A3 (en) | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses | |
NZ729519A (en) | Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin | |
CA2863981A1 (en) | Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses | |
EP2552490A4 (en) | INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF | |
CO6700818A2 (es) | Vectores de parapoxvirus | |
AU2013352179A8 (en) | Computationally optimized broadly reactive antigens for H1N1 influenza | |
CO6670515A2 (es) | Vectores de parapoxvirus | |
NZ704188A (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
EA033242B1 (ru) | Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением | |
EA201992602A2 (ru) | Вакцины против впг-2 | |
WO2012064816A3 (en) | Methods of neutralizing viral infection |